PharmTech Drug Digest 11.20
News|Articles|June 2, 2016

Pharmapack Europe Launches Start-up Hub

The Start-up Hub is designed to give start-up companies the opportunity to network at Pharmapack.

On May 31, 2016 Pharmapack Europe announced the launch of its Start-up Hub, a new addition to the 2017 event at the Paris Expo Porte de Versailles from February 1-2, 2017. According to Pharmapack, the Start-up Hub is a platform designed to give young pharmaceutical firms the ability to network at the conference for an affordable price. Companies at the Start-up Hub will have the opportunity to showcase ideas, meet potential customers, partners and investors, and forge new relationships.

According to Pharmapack, there are only ten spots available for companies in the Start-up Hub. Exhibitors will be selected by Pharmapack’s advisory board of industry experts. The board will fill available spots based on the uniqueness, market prospects, patient impact, and savings potential of each company’s innovations, Pharmapack said in a press announcement. Firms pursuing all types of pharma and biopharma packaging innovation are encouraged to apply. Entry closes on July 28, 2016 and recipients will be announced in early September.

Source: Pharmapack Europe


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.